Pharmaceutical companies, SRAs, WHO Prequalification Programme (PQ) and NRAs commit to:

Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.

Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.

  • HOME

  • 2018 DIAGNOSTICS

  • 2017 / 2018 TREATMENT

  • INDIV. COMMITMENTS

  • STAKEHOLDERS

  • HIGH LEVEL DIALOGUES

  • CALENDAR

  • UPDATES

  • LIBRARY

  • More...

    Paediatric HIV: Rome Action Plan

    2018 TREATMENT
    REGULATORY
    Action 1 - Pharma
    Action 9 - WHO
    Action 2 - EMA
    Action 10 - WHO
    Action 3 - EMA
    Action 4 - EMA
    Action 5 - USFDA
    Action 6 - USFDA
    Action 7 - USFDA
    Action 11 - WHO
    Action 12 - WHO
    Action 13 - Pharma
    Action 14 - Pharma
    Action 8 - USFDA
    Action 15 - Pharma
    FINANCING
    Action 16 - GAP-f
    Action 17 - GAP-f
    Action 19 - GAP-f
    Action 20 - Pharma
    Action 21 - Donors
    INTRODUCTION, UPTAKE AND PROCUREMENT
    Action 18 - GAP-f
    Action 22 - Donors
    Action 23 - Pharma
    Action 30 - GAP-f
    Action 24 - Pharma
    Action 25 - Pharma
    Action 26 - Pharma
    Action 27 - Pharma
    Action 28 -
    Action 29 - GAP-f
    Action 31 - GAP-f